References
- Weinberg R. A. Ras oncogenes and the molecular mechanisms of carcinogenesis. Blood 1984; 64: 1143–5
- Bishop J. M. Cellular oncogenes and retroviruses. Ann Rev Biochem 1983; 52: 301–54
- Shy T Y, Weeks M. O. Oncogenes and cancer: the p21 ras genes. Cane Inv 1984; 2: 109–23
- Hanley M R, Jackson T. The ras gene: transformer and transducer. Nature 1987; 328: 668–9
- Defeo-Jones D, Tatchell K, Robinson L C, et al. Mammalian and yeast ras gene products: biological function in their heterologous systems. Science 1985; 228: 179–84
- Needleman S W, Kraus M H, Srivastava S K, Levine P N, Aaronson S. A. High frequency of N-ras activation in acute myelogenous leukemia. Blood 1986; 67: 753–7
- Bos J L, Verlaan-de Vries M, van der Eb A J, et al. Mutations in N-ras predominant in acute myeloid leukemia. Blood 1987; 69: 1237–41
- Chang E H, Furth M E, Scolnick E M, Lowy D. R. Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey Murine sarcoma virus. Nature 1982; 479–552
- Hand P H, Thor A, Wunderlich D, Muraro R, Caruso A, Schlom J. Monoclonal antibodies of predetermined specificity detect activated ras gene expression in human mammary and colon carcinomas. Proc Natl Acad Sci USA 1984; 81: 5227–31
- Lundy J, Crimson R, Mishriki Y, et al. Elevated ras oncogene expression correlates with lymph node metastases in breast cancer patients. J Clin Oncol 1986; 4: 1321–5
- Viola M V, Fromowitz F, Oravez S, et al. Expression of ras oncogene p21 in prostate cancer. N Engl J Med 1986; 314: 133–7
- Srivastava S K, Yuasa Y, Reynold S H, Aaronson S. A. Effects of two major activating lesions on the structure and conformation of human ras oncogene products. Proc Natl Acad Sci USA 1987; 82: 38–42
- Bos J L, Fearon E R, Hamilton S R, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987; 327: 293–7
- Furth M E, Aldrich T H, Cordon-Cardo C. Expression of ras protooncogene proteins in normal human tissues. Oncogene 1987; 1: 47–58
- Gutheil J C, Mane S M, Kapil V, Needleman S. W. Immunoprecipitation of cell lysates with RAP-5 does not specifically detect ras oncogene product p21. Hum Pathol 1989; 20: 1176–80
- Samowitz W S, Paull G, Hamilton S. R. Reported binding of monoclonal antibody RAP-5 to formalin-fixed tissue sections is not indicative of ras p21 expression. Hum Pathol 1988; 19: 127–31
- Chesa P G, Rettig W J, Melamed M R, Old L. J. Expression of p21 ras in normal and malignant human tissues: lack of association with proliferation and malignancy. Proc Natl Acad Sci USA 1987; 84: 3234–8
- Studzinski G P, Brelvi Z. S. Increased expression of C-Ha-ras during granulocytic differentiation of HL60 cells. Lab Invest 1987; 56: 499–504
- Nakagawa T, Mabry M, de Bustros A, Ihle J N, Nelkin B D, Baylin S. B. Introduction of v-Ha-ras oncogene induces differentiation of cultured human medullary thyroid carcinoma cells. Proc Natl Acad Sci USA 1987; 84: 5923–7
- Mavilio F, Sposi N M, Petrini M, et al. Expression of cellular oncogenes in primary cells from human acute leukemia. Proc Natl Acad Sci USA 1986; 83: 4394–8
- Andreef M, Slater D E, Bressler J, Furth M. E. Cellular ras oncogene expression and cell cycle measured by flow cytometry in hematopoietic cell lines. Blood 1986; 67: 676–81
- Campisi J, Gray H E, Pardee A B, Dean M, Sonnenshein G. E. Cell-cycle control of c-myc but not c-ras expression in lost following chemical transformation. Cell 1984; 36: 241–7
- Tannock I. Cell kinetics and chemotherapy: a critical review. Cane Treat Rep 1978; 62: 1117–33